查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1944411

全球人工智慧藥物定序市場：按治療領域、藥物類型、最終用戶、部署方法、國家和地區分類－產業分析、市場規模、佔有率和預測（2025-2032年）

Artificial Intelligence In Drug Repurposing Market, By Therapeutic Area, By Drug Type, By End User, By Deployment Mode, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 374 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2024 年，人工智慧 (AI) 藥物定序市場規模將達到 9.9098 億美元，從 2025 年到 2032 年的複合年成長率將達到 20.10%。

人工智慧在現有藥物定序的應用是指運用智慧計算系統分析大型、複雜的生物醫學資料集，從而發現現有藥物的新用途。它利用機器學習、深度學習和自然語言處理等人工智慧技術，揭示藥物、標靶和疾病之間潛在的關聯。這些人工智慧驅動的工具能夠加速藥物發現過程，降低研發成本，並提高識別潛在治療藥物的成功率。數據分析和假設產生的自動化能夠提升製藥和生技公司的決策效率和研發效率。此外，它還有助於更快地滿足未被滿足的醫療需求，並實現更易於獲取、數據驅動且更具成本效益的藥物開發策略。

人工智慧在藥物定序的市場動態

人工智慧和機器學習在藥物研發的應用日益廣泛

人工智慧和機器學習在藥物研發領域的日益普及，指的是將先進的計算模型整合到藥物發現和開發過程中，以提高研究效率和成果的趨勢。這使得分析龐大而複雜的生物醫學資料集（包括基因組數據、臨床試驗結果和科學文獻）成為可能，從而更準確地識別新的藥物-疾病關聯。在利用人工智慧進行藥物重定位時，這種應用支援預測建模、目標分子識別以及對現有藥物庫進行快速篩檢，以尋找新的治療用途。因此，製藥公司可以縮短開發週期、降低研發成本，並改善早期研究階段的決策。此外，人工智慧和機器學習加強了跨數位研究平台的協作，實現了來自多個來源的無縫資料整合。它還支援透過真實世界數據和實驗數據不斷改進和訓練模型。總而言之，人工智慧和機器學習的日益普及正在提升現代藥物研發生態系統中藥物重定位策略的擴充性、可靠性和有效性。例如，根據美國食品藥物管理局）的數據，在藥物研發的各個階段，採用人工智慧技術的藥物申請數量顯著增加，2016年至2023年間記錄在案的AI相關申請超過500件。此外，FDA於2025年發布了一份指導文件草案，就如何負責任地使用AI來支持生技藥品和生物製品的監管決策提出了建議。此舉凸顯了FDA積極主動地促進創新，同時在AI輔助藥物研發中維持嚴格的安全性和有效性標準。這顯示監管機構和相關機構對將先進的AI和機器學習工具整合到藥物研發中給予了強力的支持。這也反映了更廣泛的行業趨勢，即數據驅動技術正被擴大用於促進藥物再利用、提高分析準確性以及最佳化研發決策。因此，基於AI的方法正在成為一種高效且經濟的策略，用於識別新的治療用途並滿足尚未滿足的醫療需求。

人工智慧藥物定序市場：細分分析

全球藥物定序人工智慧市場按治療領域、藥物類型、最終用戶、部署模式和地區進行細分。

根據治療領域，市場可分為三大類：腫瘤學、神經病學和心血管疾病。腫瘤學領域在人工智慧藥物定序市場中佔據顯著佔有率，因為其能夠加速現有抗癌藥物新用途的發現。加速腫瘤藥物研發需要利用先進技術，透過分析大型資料集、臨床試驗結果和分子交互作用，縮短識別有效抗癌治療方法所需的時間。這個過程利用人工智慧演算法、預測建模和機器學習來最佳化候選藥物的選擇並簡化研究工作流程。加快藥物發現速度可以提高研發效率、降低開發成本，並有助於快速提供可能挽救生命的治療方法。人工智慧驅動的藥物重定位透過計算篩檢、標靶預測和數據驅動的洞察來實現這一加速，使研究人員能夠快速識別、檢驗和優先排序有前景的腫瘤候選藥物。例如，根據世界衛生組織（世衛組織）發布的《2024年全球癌症負擔報告》，預計2022年全球將新增2,000萬例癌症病例，970萬人死於癌症，約有5,350萬人能在確診癌症後的五年內存活。這些數據凸顯了全球癌症負擔的快速加重，並顯示各衛生系統迫切需要改善癌症的預防、早期發現和治療服務。

根據藥物類型，市場可分為兩大類：小分子藥物和生技藥品。小分子藥物憑藉其廣泛的適用性和完善的安全性記錄，在人工智慧藥物定序市場中佔據最大佔有率。豐富的歷史數據和臨床數據為其優勢提供了有力支撐，使人工智慧演算法能夠高效地分析分子結構、預測標靶相互作用並識別有前景的重定位機會。與從頭開始的藥物研發相比，該領域能夠實現更快、更經濟的藥物開發，從而更快轉化為臨床應用。此外，小分子藥物還具有許多優勢，例如可擴展的人工智慧驅動工作流程、跨多個治療領域的適用性以及在重定位舉措中取得的穩定結果，使其成為市場關注的焦點。例如，根據《巨量資料驅動醫療保健的重大變革》報告，生物醫學和臨床數據量正呈指數級成長，PubMed收錄的生物醫學論文超過2300萬篇，僅當年就新增了約100萬篇。這反映了研究和臨床資訊的快速成長。報導進一步強調，超過80%的醫療保健數據為非結構化數據，包括臨床記錄和說明記錄，凸顯了醫療保健數據的規模、種類和複雜性，以及這些數據在研究、分析和數據驅動決策中的應用。這種廣泛應用表明，數位化製藥和生物醫學研究基礎設施已日趨成熟。這也反映了更廣泛的趨勢，即人工智慧驅動的技術正在實現對臨床和分子數據的可擴展訪問，提高研究平台間的互通性，並擴大人工智慧解決方案在藥物重定位和藥物發現中的應用。

人工智慧在藥物定序市場的應用—區域分析

由於製藥研發基礎設施、醫療保健體係以及人工智慧技術應用方面的差異，人工智慧藥物定序市場呈現出顯著的區域差異。北美，尤其是美國和加拿大，在強大的生物技術和製藥研究網路、人工智慧驅動的藥物再利用平台的廣泛應用以及對創新治療方法的旺盛需求的推動下，市場持續保持強勁成長。歐洲市場也持續穩步擴張，這得益於製藥研發投入的增加、監管機構對基於人工智慧的藥物開發的支持以及可互通的臨床和分子數據系統的整合。在亞太地區，不斷成長的製藥研究舉措、大規模的患者群體、政府的支持政策以及生物技術公司與學術機構之間的合作，正在為中國、印度、日本和韓國等國家帶來顯著的市場動力。同時，拉丁美洲以及中東和非洲地區正透過加強臨床研究基礎設施、改善分子和臨床資料集的獲取以及提高對人工智慧驅動的藥物再利用解決方案的認知度，逐步鞏固其市場地位。

美國人工智慧藥物定序市場—國家分析

在美國強大的製藥和生物技術基礎以及人工智慧藥物發現平台日益普及的推動下，美國藥物定序人工智慧市場正穩步發展。研究機構、生物技術公司和製藥公司正擴大利用人工智慧來發現現有藥物的新用途、最佳化研發流程並加速臨床開發進程。主要技術供應商的加入以及監管機構對人工智慧驅動藥物開發的支持進一步推動了市場成長。此外，提高效率、降低開發成本和加快治療方法上市速度的趨勢也加速了美國製藥業對人工智慧藥物重定位解決方案的採用。

根據英國政府加速人工智慧驅動藥物研發的計劃，英國將支持OpenBind聯盟，目標是在五年內產生超過50萬個實驗性蛋白質-配體複合物結構和親和性測量數據，相當於過去50年產生的公共數據總量的20倍。這項由政府資助和戰略合作推動的計劃，旨在擴展高品質的生物醫學資料集，並加速英國人工智慧驅動的藥物研發。

目錄

第1章 人工智慧藥物定序市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章 人工智慧在藥物定序的關鍵市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

第4章 人工智慧在藥物定序市場的應用：產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長展望：概覽
  • 管理體制分析

第5章 人工智慧在藥物定序市場的應用：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 人工智慧在藥物定序的市場現狀

  • 人工智慧藥物定序市場佔有率分析（2024 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

7. 人工智慧在藥物定序市場（依治療領域分類）

  • 概述
    • 細分市場佔有率分析：依治療領域分類
    • 代謝性疾病
    • 瘤
    • 罕見疾病
    • 感染疾病
    • 神經病學
    • 免疫學
    • 循環系統疾病
    • 其他

第8章 人工智慧在藥物定序市場的應用（按藥物類型分類）

  • 概述
    • 細分市場佔有率分析：依藥物類型分類
    • 胜肽
    • 疫苗
    • 低分子化合物
    • 生技藥品
    • 其他

9. 人工智慧在藥物定序市場的應用（依最終用戶分類）

  • 概述
    • 細分市場佔有率分析：依最終用戶分類
    • 醫療保健提供者
    • 學術和研究機構
    • 製藥和生物技術公司
    • 受託研究機構（CRO）
    • 其他

第10章 人工智慧在藥物定序的市場應用（以部署方式分類）

  • 概述
    • 細分市場佔有率分析：依藥物類型分類
    • 本地部署
    • 基於雲端的

第11章 區域藥物定序人工智慧市場

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第12章 主要供應商分析：人工智慧在藥物定序產業的應用

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Cyclica Inc.
    • BioAge Labs, Inc.
    • BostonGene Corporation
    • Insilico Medicine, Inc.
    • Healx Ltd.
    • Ignota Labs Ltd.
    • Atomwise, Inc.
    • Ginkgo Bioworks Holdings, Inc.
    • United Therapeutics Corporation
    • Recursion Pharmaceuticals, Inc.
    • TxGNN, Inc.
    • Exscientia plc
    • BioXcel Therapeutics, Inc.
    • BenevolentAI Limited
    • Melior Discovery, Inc.
    • Others

第13章：分析師視角360度分析

簡介目錄
Product Code: ANV6014

Artificial Intelligence In Drug Repurposing Market size was valued at US$ 990.98 Million in 2024, expanding at a CAGR of 20.10% from 2025 to 2032.

Artificial Intelligence in Drug Repurposing refers to the application of intelligent computational systems that identify new therapeutic uses for existing drugs by analyzing large, complex biomedical datasets. It leverages artificial intelligence technologies, such as machine learning, deep learning, and natural language processing, to uncover hidden relationships among drugs, targets, and diseases. These AI-driven tools help accelerate drug discovery timelines, reduce development costs, and improve the success rate of identifying viable treatment candidates. By automating data analysis and hypothesis generation, they enhance decision-making and research efficiency within pharmaceutical and biotechnology organizations. Artificial intelligence in drug repurposing also supports faster responses to unmet medical needs and enables more accessible, data-driven, and cost-effective drug development strategies.

Artificial Intelligence In Drug Repurposing Market- Market Dynamics

Increasing adoption of AI and machine learning in pharmaceutical R&D

Increasing adoption of AI and machine learning in pharmaceutical R&D refers to the growing integration of advanced computational models within drug discovery and development processes to improve research efficiency and outcomes. It enables the analysis of vast and complex biomedical datasets, including genomic data, clinical trial results, and scientific literature, to identify novel drug disease relationships with greater accuracy. In artificial intelligence driven drug repurposing, this adoption supports predictive modeling, target identification, and rapid screening of existing drug libraries for new therapeutic applications. As a result, pharmaceutical companies are able to reduce development timelines, lower R&D costs, and improve decision-making in early-stage research. Moreover, AI and machine learning enhance collaboration across digital research platforms, enabling seamless data integration from multiple sources. They also support continuous model refinement and learning through real-world and experimental data. Overall, the increasing use of AI and machine learning strengthens the scalability, reliability, and effectiveness of drug repurposing strategies in modern pharmaceutical R&D ecosystems. For example, according to the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER), the number of drug application submissions incorporating artificial intelligence has risen markedly across the drug development lifecycle, with over 500 AI-related submissions recorded between 2016 and 2023. In addition, the FDA released draft guidance in 2025 providing recommendations on the responsible use of AI to support regulatory decision-making for drug and biological products. This development highlights the FDA's proactive approach to encouraging innovation while maintaining rigorous standards for safety and efficacy in AI-enabled drug development. This underscores solid regulatory and institutional backing for the integration of advanced AI and machine learning tools within pharmaceutical research and development. It also reflects wider industry trends where data-driven technologies are being increasingly adopted to accelerate drug repurposing, enhance analytical accuracy, and optimize R&D decision-making. Consequently, AI-enabled approaches are emerging as efficient and cost-effective strategies for identifying new therapeutic applications and addressing unmet medical needs.

Artificial Intelligence In Drug Repurposing Market- Segmentation Analysis:

The Global Artificial Intelligence in Drug Repurposing Market is segmented by Therapeutic Area, Drug Type, End User, Deployment Mode, and Region.

The market is divided into three categories based on Therapeutic Area Oncology, Neurology, and Cardiovascular Diseases. The Oncology segment represents a significant portion of the Artificial Intelligence in Drug Repurposing market due to its capacity to speed up the discovery of new therapeutic uses for existing cancer drugs. Accelerating drug discovery in oncology involves using advanced technologies to reduce the time required to identify effective cancer treatments by analyzing extensive datasets, clinical trial outcomes, and molecular interactions. This process leverages AI-powered algorithms, predictive modeling, and machine learning to optimize candidate selection and streamline research workflows. Shortening discovery timelines improves R&D efficiency, lowers development costs, and enables faster delivery of potentially life-saving therapies. In AI-driven drug repurposing, this acceleration is achieved through computational screening, target prediction, and data-driven insights, allowing researchers to rapidly identify, validate, and prioritize promising oncology drug candidates. For instance, according to the World Health Organization's 2024 report on the global cancer burden, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022, with approximately 53.5 million people living within five years of a cancer diagnosis. These figures underscore the rapidly increasing global cancer burden and highlight the urgent need for improved prevention, early detection, and treatment services across healthcare systems.

The market is divided into two categories based on Drug Type: Small Molecule Drugs and Biologics. The Small Molecule Drugs segment accounts for the largest share of the Artificial Intelligence in Drug Repurposing market, driven by its extensive applicability and well-documented safety profiles. Its dominance is supported by the availability of rich historical and clinical data, which allows AI algorithms to efficiently analyze molecular structures, predict target interactions, and identify promising repurposing opportunities. This segment enables faster and more cost-effective drug development compared with new drug discovery, supporting quicker clinical translation. Additionally, small molecules benefit from scalable AI-driven workflows, applicability across multiple therapeutic areas, and consistent outcomes in repurposing initiatives, making them a key focus in the market. For instance, according to the Big Data in Medicine is Driving Big Changes, the volume of biomedical and clinical data has grown exponentially, with over 23 million biomedical articles indexed in PubMed, and nearly one million new publications added that year alone, reflecting the rapidly increasing availability of research and clinical information. The article also highlights that more than 80 % of healthcare data is unstructured, including clinical notes and narrative records, underscoring the scale, diversity, and complexity of medical data now being generated and leveraged for research, analysis, and data-driven decision-making. This extensive adoption underscores the maturity of digital pharmaceutical and biomedical research infrastructure. It reflects broader trends in which AI-driven technologies are enabling scalable access to clinical and molecular data, improved interoperability across research platforms, and the expanded use of AI-based solutions for drug repurposing and discovery.

Artificial Intelligence In Drug Repurposing Market- Geographical Insights

The Artificial Intelligence in Drug Repurposing market demonstrates significant regional variation, influenced by differences in pharmaceutical R&D infrastructure, healthcare systems, and AI technology adoption. North America continues to exhibit strong activity, supported by robust biotech and pharmaceutical research networks, widespread use of AI-driven drug repurposing platforms, and high demand for innovative therapeutics, particularly in the U.S. and Canada. Europe is witnessing consistent expansion, backed by growing investments in pharmaceutical research, regulatory support for AI-based drug development, and integration of interoperable clinical and molecular data systems. In Asia Pacific, increasing pharmaceutical research initiatives, large patient populations, supportive government policies, and partnerships between biotech firms and academic institutions are contributing to notable market momentum in countries such as China, India, Japan, and South Korea. Meanwhile, Latin America, the Middle East, and Africa are gradually strengthening their market presence through enhanced clinical research infrastructure, improved access to molecular and clinical datasets, and growing awareness of AI-enabled drug repurposing solutions.

United States Healthcare Virtual Assistant Market - Country Insights

The United States Artificial Intelligence in Drug Repurposing market is advancing steadily, fueled by a strong pharmaceutical and biotech infrastructure and the growing adoption of AI-powered drug discovery platforms. Research institutions, biotech firms, and pharmaceutical companies are increasingly using AI to uncover new therapeutic applications for existing drugs, optimize R&D workflows, and accelerate clinical development timelines. Engagement from leading technology providers, along with regulatory support for AI-driven drug development, is further promoting market growth. Moreover, the emphasis on improving efficiency, reducing development costs, and bringing therapies to market faster is accelerating the uptake of AI-enabled drug repurposing solutions across the U.S. pharmaceutical sector.

According to a UK Government announcement on advancing AI-driven drug discovery, the UK aims to support the OpenBind consortium in generating over 500,000 experimental protein-ligand complex structures and affinity measurements over five years, marking a 20-fold increase compared with all public data produced over the past 50 years. This effort is backed by government funding and strategic collaborations to expand high-quality biomedical datasets and accelerate AI-enabled drug research and development across the country.

Artificial Intelligence In Drug Repurposing Market- Competitive Landscape:

The Artificial Intelligence in Drug Repurposing market is moderately concentrated, with a number of leading pharmaceutical, biotech, and AI-focused technology companies driving competition. Prominent players include IBM Watson Health, Exscientia, Insilico Medicine, Healx, BenevolentAI, Recursion Pharmaceuticals, Atomwise, Evotec, BioAge Labs, Cyclica, Schrodinger, and In Silico Trials. These companies compete by providing AI-powered platforms that identify new therapeutic applications for existing drugs, streamline R&D processes, predict drug-target interactions, and accelerate clinical development timelines. They differentiate themselves through capabilities such as deep learning-driven drug discovery, large-scale biomedical data analytics, integration with research databases, and cloud-based computational platforms, enabling faster, more efficient, and cost-effective drug repurposing.For example, in 2023, Exscientia entered a multi-target collaboration with Merck KGaA, leveraging its AI-powered drug discovery platform to accelerate the design of novel therapeutics, with an upfront payment of USD 20 million and potential milestone payments exceeding USD 670 million. By 2024, Exscientia further expanded its platform capabilities through a partnership with Amazon Web Services (AWS), enabling cloud-based computational drug design and large-scale data analytics. The market is driven by rising demand for efficient, data-driven, and AI-enabled drug repurposing solutions, particularly in oncology and rare diseases. Additionally, companies are enhancing their platforms with predictive modeling, deep learning algorithms, and cloud-based deployments to meet the growing need for faster, cost-effective, and precise identification of new therapeutic applications for existing drugs.

Recent Developments:

In November 2024, Recursion Pharmaceuticals completed a business combination with Exscientia, creating a unified AI-powered drug discovery platform that integrates both companies' technologies and pipelines to advance drug discovery and development with enhanced computational capabilities. This combined entity features more than 10 clinical and preclinical programs and aims to reduce discovery timelines and costs through iterative AI-driven research loops.

In July 2024, Insilico Medicine announced a collaboration with Inimmune to leverage its proprietary AI platform, Chemistry42, to accelerate the discovery and development of future immunotherapeutics, marking a strategic expansion of its AI-based drug design capabilities into novel therapeutic areas and reinforcing the role of AI in identifying and optimizing drug candidates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Cyclica Inc.
  • BioAge Labs, Inc.
  • BostonGene Corporation
  • Insilico Medicine, Inc.
  • Healx Ltd.
  • Ignota Labs Ltd.
  • Atomwise, Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • United Therapeutics Corporation
  • Recursion Pharmaceuticals, Inc.
  • TxGNN, Inc.
  • Exscientia plc
  • BioXcel Therapeutics, Inc.
  • BenevolentAI Limited
  • Melior Discovery, Inc.
  • Others

GLOBALARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Metabolic Disorders
  • Oncology
  • Rare Diseases
  • Infectious Diseases
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Peptides
  • Vaccines
  • Small Molecules
  • Biologics
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Healthcare Providers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

  • On-premises
  • Cloud-based

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Artificial Intelligence In Drug Repurposing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Artificial Intelligence In Drug Repurposing Market Snippet by Therapeutic Area
    • 2.1.2. Artificial Intelligence In Drug Repurposing Market Snippet by Drug Type
    • 2.1.3. Artificial Intelligence In Drug Repurposing Market Snippet by End User
    • 2.1.4. Artificial Intelligence In Drug Repurposing Market Snippet by Deployment Mode
    • 2.1.5. Artificial Intelligence In Drug Repurposing Market Snippet by Country
    • 2.1.6. Artificial Intelligence In Drug Repurposing Market Snippet by Region
  • 2.2. Competitive Insights

3. Artificial Intelligence In Drug Repurposing Key Market Trends

  • 3.1. Artificial Intelligence In Drug Repurposing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Artificial Intelligence In Drug Repurposing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Artificial Intelligence In Drug Repurposing Market Opportunities
  • 3.4. Artificial Intelligence In Drug Repurposing Market Future Trends

4. Artificial Intelligence In Drug Repurposing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Artificial Intelligence In Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Artificial Intelligence In Drug Repurposing Market Landscape

  • 6.1. Artificial Intelligence In Drug Repurposing Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Artificial Intelligence In Drug Repurposing Market - By Therapeutic Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
    • 7.1.2. Metabolic Disorders
    • 7.1.3. Oncology
    • 7.1.4. Rare Diseases
    • 7.1.5. Infectious Diseases
    • 7.1.6. Neurology
    • 7.1.7. Immunology
    • 7.1.8. Cardiovascular Diseases
    • 7.1.9. Others

8. Artificial Intelligence In Drug Repurposing Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
    • 8.1.2. Peptides
    • 8.1.3. Vaccines
    • 8.1.4. Small Molecules
    • 8.1.5. Biologics
    • 8.1.6. Others

9. Artificial Intelligence In Drug Repurposing Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
    • 9.1.2. Healthcare Providers
    • 9.1.3. Academic & Research Institutes
    • 9.1.4. Pharmaceutical & Biotechnology Companies
    • 9.1.5. Contract Research Organizations (CROs)
    • 9.1.6. Others

10. Artificial Intelligence In Drug Repurposing Market - By Deployment Mode

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
    • 10.1.2. On-premises
    • 10.1.3. Cloud-based

11. Artificial Intelligence In Drug Repurposing Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APACMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.5. APACMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APACMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.7. APACMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. PhilippinesMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.4. PhilippinesMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. PhilippinesMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.15.6. PhilippinesMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAMMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAMMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAMMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAMMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEAMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.5. MEAMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEAMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.7. MEAMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. IsraelMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.4. IsraelMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. IsraelMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.10.6. IsraelMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Artificial Intelligence In Drug Repurposing Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Cyclica Inc.
    • 12.2.2. BioAge Labs, Inc.
    • 12.2.3. BostonGene Corporation
    • 12.2.4. Insilico Medicine, Inc.
    • 12.2.5. Healx Ltd.
    • 12.2.6. Ignota Labs Ltd.
    • 12.2.7. Atomwise, Inc.
    • 12.2.8. Ginkgo Bioworks Holdings, Inc.
    • 12.2.9. United Therapeutics Corporation
    • 12.2.10. Recursion Pharmaceuticals, Inc.
    • 12.2.11. TxGNN, Inc.
    • 12.2.12. Exscientia plc
    • 12.2.13. BioXcel Therapeutics, Inc.
    • 12.2.14. BenevolentAI Limited
    • 12.2.15. Melior Discovery, Inc.
    • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us